Beam Therapeutics (BEAM) Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Assets data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Assets rose 0.95% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 0.95% YoY) and the FY2025 annual result came in at $1.5 billion, up 34.19% from the prior year.
• Assets held at $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Assets topped out at $1.5 billion in Q4 2025 and bottomed at $1.1 billion in Q4 2024.
• The 5-year median for Assets is $1.4 billion (2023), against an average of $1.4 billion.
• The widest annual swing landed in 2022, when Assets surged 109.65%; it then declined 24.38% in 2024.
• Tracing BEAM's Assets over 5 years: stood at $1.3 billion in 2022, then grew by 8.79% to $1.5 billion in 2023, then declined by 24.38% to $1.1 billion in 2024, then jumped by 34.19% to $1.5 billion in 2025, then retreated by 0.03% to $1.5 billion in 2026.
• Per Business Quant, the three latest BEAM Assets figures stand at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025).

Peer Comparison